GeneDx Holdings (NASDAQ: WGS) reported Q2 EPS of ($1.10), $0.46 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $70.51 million versus the consensus estimate of $59.8 million.

GUIDANCE

GeneDx Holdings sees full year 2024 revenues1 between $255 and $265 million versus the consensus of $242.4 million.

For earnings history and earnings-related data on GeneDx Holdings (WGS) click here.